Form 10-Q Voyager Therapeutics, For: Sep 30
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Voyager Therapeutics (VYGR) PT Lowered to $27 at Baird
November 8, 2018 8:44 AM ESTBaird analyst Brian Skorney lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $27.00 (from $31.00) while maintaining a Outperform rating.
The analyst commented, "After initially indicating that the Phase 2 study Voyager is about to start could be fileable, the FDA recently notified Voyager... More
